Related references
Note: Only part of the references are listed.A Multi-Institutional Experience of Isolated Limb Infusion: Defining Response and Toxicity in the US
Georgia M. Beasley et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2009)
Regional Therapeutic Strategies in Melanoma: Not Just Local Disease Control, but an Opportunity to Develop Novel Therapeutic Strategies with Potential Implications for Systemic Therapy
Douglas Tyler
ANNALS OF SURGICAL ONCOLOGY (2008)
Isolated limb infusion for in-transit malignant melanoma of the extremity: A well-tolerated but less effective alternative to hyperthermic isolated limb perfusion
Georgia M. Beasley et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Outcomes Following Isolated Limb Infusion for Melanoma. A 14-Year Experience
Hidde M. Kroon et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group trial Z0020
Wendy R. Cornett et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity
Mary S. Brady et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Efficacy of repeat isolated limb perfusions with tumor necrosis factor α and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure
DJ Grünhagen et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
Share Paper
